Director - Research
Evommune, Inc
Palo Alto, California, United States
Disclosure information not submitted.
EVO756: A Promising Oral MRGPRX2 Inhibitor Showing Strong Preclinical and Phase 1 Results
Wednesday, June 25, 2025
1:25pm - 1:40pm East Coast USA Time
